Piper Sandler Maintains Nuvalent(NUVL.US) With Buy Rating, Raises Target Price to $100
Nuvalent Initiated at Overweight by Barclays
Nuvalent Analyst Ratings
Barclays Initiates Nuvalent(NUVL.US) With Buy Rating, Announces Target Price $100
Nuvalent (NUVL) Receives a Buy From Barclays
Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Nuvalent (NUVL) and Dianthus Therapeutics (DNTH)
Buy Rating Affirmed for Nuvalent Amid Promising NVL-655 Clinical Trial Progress and Anticipated Efficacy Superiority
Analysts Offer Insights on Healthcare Companies: Nuvalent (NUVL) and Next Science Ltd (OtherNXSCF)
Jefferies Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $97
Analysts Offer Insights on Healthcare Companies: Nuvalent (NUVL) and Alphatec Holdings (ATEC)
Nuvalent's Promising Clinical Data and Differentiation in NSCLC Trials Bolster Buy Rating
Nuvalent Analyst Ratings
Nuvalent Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Bluebird Bio (BLUE) and Nuvalent (NUVL)
Nuvalent (NUVL) Gets a Buy From Stifel Nicolaus
Nuvalent's Promising Clinical Progress and Financial Stability Support Strong Buy Rating
Nuvalent Analyst Ratings
Nuvalent Analyst Ratings
Nuvalent Analyst Ratings
Nuvalent Analyst Ratings